The role and efficacy of pemetinib/pemetinib

Pemigatinib/Pemigatinib, as a highly selective FGFR inhibitor, provides a new treatment option for patients with advanced cholangiocarcinoma and myeloid/lymphoid tumors associated with FGFR1 rearrangement. It inhibits the activity of FGFR and blocks the growth and spread signals of cancer cells, thereby achieving effective treatment of these malignant tumors. In clinical trials, pemetinib has shown good efficacy and safety, bringing patients better survival chances and quality of life.

Pemetinib inhibitsFGFR1, FGFR2 and FGFR3, blocking their signaling pathways and reducing cell viability in cancer cell lines, activating FGFR amplification and fusion, leading to constitutive activation of FGFR signaling. Genetic alterations of FGFR1, FGFR2, and FGFR3 (such as amplification, missense, or fusion mutations in the coding region) leading to constitutive activation of the FGFR signaling pathway have been observed in various tumors. However, alterations in the FGFR gene, demonstrated in selected patients, do not always mean the development of oncogenes. Therefore, fusion or rearrangement of FGFRs must be experimentally demonstrated before starting drug treatment. Pemetinib can target these abnormal genetic changes and inhibit the growth and spread of cancer cells by inhibiting the activity of FGFR2.

In clinical trials, pemetinib has shown good efficacy in treating patients with cholangiocarcinoma. According to research data, the intrahepatic cholangiocarcinoma-targeting drug pemetinib can achieve an objective response rate of 35.5% when treating patients with cholangiocarcinoma, and the disease control rate can reach 82%. This means that more patients can effectively control their disease and improve their quality of life after receiving pemetinib treatment. In addition, the median duration of response was 9.1 months, with as many as 63% of patients experiencing a response lasting ≥6 months, and 18% of patients experiencing a response lasting ≥12 months. These data demonstrate that pemetinib has a significant effect on disease control and improving prognosis of intrahepatic cholangiocarcinoma.